The 0.25mg Wegovy dose: what it does and what comes next

Step 1: why treatment opens at 0.25mg, not higher

Semaglutide slows the movement of food through the stomach and acts on appetite-regulating receptors in the brain. Both effects are dose-dependent, which means stronger doses produce a more pronounced response, including a stronger chance of nausea, vomiting and other gastrointestinal discomfort in the early weeks. If you want to understand what this starting point involves before your first injection, our guide to the 0.25mg semaglutide dose covers what to expect and why treatment begins here rather than at a higher level.

A question our prescribers hear most weeks is whether staying on 0.25mg longer than four weeks is a sign something has gone wrong. It is not. Some people need a longer settling-in period, particularly those who are more sensitive to GI effects. What matters is that any decision to hold a dose or move forward is made with your prescriber, based on how you are actually feeling, not on a fixed calendar. The reasons some people stay on 0.25mg for an extended period are well understood and medically valid.

The NHS medicines information on semaglutide (Wegovy) sets out the full dosing pathway and common reactions at each stage, and it is worth reading before your first injection.

Step 2: what 0.25mg actually feels like in practice

For many people, the first four weeks pass with only mild effects. Appetite may dip slightly. Nausea, if it appears, tends to be at its most noticeable in the day or two after the injection and then eases. Fatigue and mild headache are reported by some. These early effects typically settle as the body adapts, they are not a signal to stop, but they are worth noting and sharing with your prescriber.

The injection itself is subcutaneous, meaning it goes into the fatty tissue just beneath the skin. Suitable sites are the abdomen, the upper thigh, or the upper arm. Rotating between sites each week reduces the chance of localised skin reactions. For a fuller picture of what early treatment involves, the Wegovy overview on this site covers the mechanism, the injection process and what the clinical evidence shows.

Storage during this first month follows the same rules as all subsequent doses: keep the pen refrigerated between 2°C and 8°C, and refer to the Patient Information Leaflet for the specific window during which the pen can be kept at room temperature if needed for travel or convenience.

Step 3: moving from 0.25mg toward the maintenance dose

After four weeks at 0.25mg, the standard step is to 0.5mg, then 1.0mg, then 1.7mg, and finally 2.4mg, each level held for approximately four weeks. This is the dose titration pathway described in the licensed indication and reviewed in NICE's appraisal of semaglutide for weight management (TA875). The 2.4mg level is where the majority of the clinical trial data on weight outcomes was generated.

It is at the higher doses that meaningful, sustained weight reduction tends to become apparent. The STEP 1 trial, which enrolled adults with obesity and ran for 68 weeks at the 2.4mg dose, found an average weight reduction of around 15% of body weight. Those results were at maintenance dose, not at 0.25mg, context that matters when readers search for whether the 0.25mg dose is effective on its own.

The pace of titration is not fixed absolutely. If side effects at any step are disruptive, a prescriber may recommend staying at the current dose for an additional four weeks before increasing. This is not a failure of treatment; it is the process working as it should. The semaglutide guide on this site explains how the medicine works across the full dose range and what to expect at each stage.

Side effects to know about from the first dose onward

The most common side effects across the Wegovy dose range are gastrointestinal: nausea, loose stools, constipation, indigestion and, less commonly, vomiting. At 0.25mg these are generally mild compared with higher doses, but individual responses vary. Staying well hydrated, eating smaller meals, and avoiding very fatty or spicy food in the early weeks can help manage them.

There are some symptoms that require prompt medical attention at any dose. Severe, persistent abdominal pain that spreads to the back (with or without vomiting) should be assessed urgently, as the MHRA's January 2026 Drug Safety Update highlighted acute pancreatitis as a known, if infrequent, risk with GLP-1 medicines. Gallbladder symptoms, signs of a serious allergic reaction, and significant mood changes also warrant contact with a healthcare professional without delay. Yellow Card reporting for any suspected adverse effect is available at yellowcard.mhra.gov.uk.

Wegovy is not recommended during pregnancy or breastfeeding, or for anyone actively trying to conceive. It is not licensed for use in people under 18. If you are taking oral contraceptives, discuss this with your prescriber before starting treatment. Semaglutide's interaction with absorption of the pill is less clearly defined than tirzepatide's, but it is still worth raising at your consultation.

If you have questions about whether Wegovy is appropriate for your circumstances, or want to understand the full cost of a private prescription, the Wegovy cost page explains what a legitimate private prescription includes and what to look for when comparing providers. When you are ready to speak to a prescriber, start your free consultation with our clinical team.